Masimo Corp Stock Price, News & Analysis

Masimo (NASDAQ: MASI) has announced the sale of its Sound United consumer audio business to HARMAN International, a Samsung Electronics subsidiary, for $350 million in cash. The transaction, expected to close by the end of 2025, aligns with Masimo's strategic focus on its core professional healthcare segment.

The deal will integrate Sound United's premium audio brands, including Bowers & Wilkins, Denon, and Marantz, into HARMAN's existing portfolio of JBL, Harman Kardon, and other brands. This strategic move, led by CEO Katie Szyman, aims to streamline Masimo's operations and redirect resources toward addressing unmet clinical needs while driving growth and operational efficiencies.

Masimo (MASI) reported strong Q1 2025 financial results with GAAP revenue of $372 million, up 10% year-over-year. The company achieved non-GAAP earnings per diluted share of $1.36, representing a 56% growth compared to the previous year. However, the company reported a $218 million loss from discontinued operations, including a $295 million impairment of intangibles for its non-healthcare consumer business. New CEO Katie Szyman expressed confidence in Masimo's technology advantage and team strength. For 2025, Masimo updated its guidance to include the impact of new tariffs, projecting non-GAAP revenue of $1.5-1.53 billion (8-11% growth) and non-GAAP earnings per diluted share of $4.80-$5.15, down from the previous $5.30-$5.60 range due to tariff impacts. The company is developing mitigation plans to address tariff challenges through adjusted product sourcing and operations.

Masimo (NASDAQ: MASI) has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025, after market close. The results will cover the period ended March 29, 2025.

The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to review the results, led by CEO Katie Szyman and CFO Micah Young. Participants must register online to receive dial-in details and a registrant ID. A replay will be available after the call and archived on Masimo's website.

Masimo (NASDAQ: MASI) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's management will present on Wednesday, April 9, 2025 at 2:15 p.m. Eastern time.

A live webcast of the presentation will be accessible through the company's website at www.masimo.com, with a replay option available after the live event.

Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, has appointed Jon Coleman as Chief Commercial Officer. Coleman brings over 30 years of global commercial leadership experience and will oversee Dexcom's global commercial organization, including sales, marketing, and customer experience.

Coleman previously served as an executive officer at Masimo (NASDAQ: MASI) for 15 years, where he was president of commercial teams. He managed worldwide hospital sales, OEM, alternate care sales, clinical teams, and customer service. Prior to Masimo, Coleman held leadership positions at Pfizer (NYSE: PFE) Consumer Healthcare, including vice president and general manager of Canada and the Caribbean region, with additional experience in Asia and Latin America.

Throughout his career, Coleman has demonstrated success in scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.

Masimo (NASDAQ: MASI) has announced its participation in the 46th Annual Raymond James Institutional Investor Conference. The company's management will present on Tuesday, March 4, 2025 at 11:35 a.m. Eastern time. Investors and interested parties can access a live webcast of the presentation through Masimo's website. Additionally, a replay of the webcast will be made available after the live presentation concludes.

Masimo (MASI) reported its Q4 and full-year 2024 financial results, showing mixed performance across segments. Q4 consolidated revenue reached $601 million, up 9% year-over-year, with healthcare revenue at $368 million (+8%) and non-healthcare revenue at $232 million (+11%).

For full-year 2024, consolidated revenue was $2,094 million (+2%), with healthcare revenue growing 9% to $1,395 million, while non-healthcare revenue declined 10% to $699 million. The company reported a GAAP net loss per basic share of ($5.72), impacted by goodwill and intangibles impairment for Sound United. However, non-GAAP earnings per diluted share grew 16% to $4.40.

Looking ahead, Masimo's 2025 guidance projects healthcare revenue between $1,500-$1,530 million (+8-11%), with non-GAAP earnings per diluted share estimated at $5.10-$5.40.

Masimo (NASDAQ: MASI) has announced significant leadership changes effective February 12, 2025. Katie Szyman, currently worldwide president of Advanced Patient Monitoring at BD, has been appointed as the new CEO. Michelle Brennan, who served as Interim CEO, has been named Chairman of the Board, while Lead Independent Director Quentin Koffey becomes Vice Chairman.

Szyman brings over 35 years of experience, notably leading Edwards Lifesciences' Critical Care product group before its acquisition by BD in September 2024. Her appointment follows an extensive search process by Korn Ferry. The Board selected Szyman for her track record in accelerating revenue growth, experience in bringing new patient monitoring products to market, and success in leading industry talent.

The Board continues its previously announced strategic review of alternatives for both consumer audio and consumer healthcare businesses, with Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as legal advisor.

Masimo (MASI) has released preliminary financial results for Q4 and full-year 2024, along with 2025 guidance. Q4 2024 consolidated revenue is expected to reach $601 million, showing 9% growth. This includes healthcare revenue of $368 million (+8%) and non-healthcare revenue of $232 million (+11%).

For full-year 2024, consolidated revenue is anticipated at $2,094 million (+2%), with healthcare revenue at $1,395 million (+9%) and non-healthcare revenue at $699 million (-10%). Non-GAAP earnings per diluted share is expected to exceed $4.10, reaching the high end of previous guidance.

Looking ahead to 2025, Masimo projects healthcare revenue between $1,500-1,530 million (8-11% growth), Non-GAAP operating profit of $398-406 million (26.5% margin), and Non-GAAP earnings per diluted share of $4.90-5.10. The company is excluding Sound United from non-GAAP measures due to ongoing separation plans.